As of 2025-07-14, the Intrinsic Value of Jiangxi Fushine Pharmaceutical Co Ltd (300497.SZ) is 1.96 CNY. This 300497.SZ valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 9.62 CNY, the upside of Jiangxi Fushine Pharmaceutical Co Ltd is -79.60%.
The range of the Intrinsic Value is 1.11 - 3.61 CNY
Based on its market price of 9.62 CNY and our intrinsic valuation, Jiangxi Fushine Pharmaceutical Co Ltd (300497.SZ) is overvalued by 79.60%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (15.46) - (8.54) | (10.64) | -210.6% |
| DCF (Growth 10y) | (5.24) - (6.39) | (5.61) | -158.3% |
| DCF (EBITDA 5y) | 1.11 - 3.61 | 1.96 | -79.6% |
| DCF (EBITDA 10y) | 3.59 - 8.95 | 5.48 | -43.1% |
| Fair Value | -2.47 - -2.47 | -2.47 | -125.64% |
| P/E | (9.53) - (9.66) | (9.87) | -202.6% |
| EV/EBITDA | (9.25) - 1.27 | (4.39) | -145.7% |
| EPV | (9.52) - (11.65) | (10.58) | -210.0% |
| DDM - Stable | (3.23) - (8.80) | (6.02) | -162.5% |
| DDM - Multi | (1.28) - (2.80) | (1.77) | -118.3% |
| Market Cap (mil) | 5,291.00 |
| Beta | 1.65 |
| Outstanding shares (mil) | 550.00 |
| Enterprise Value (mil) | 6,688.11 |
| Market risk premium | 6.13% |
| Cost of Equity | 11.87% |
| Cost of Debt | 5.00% |
| WACC | 9.85% |